Insights from ASCO GU: An Exclusive Interview with UBC’s Marie-Pier St-Laurent | Oncology Frontier

Insights from ASCO GU: An Exclusive Interview with UBC’s Marie-Pier St-Laurent | Oncology Frontier

2024.01.31
Welcome to a special feature by Oncology Frontier, where we bridge the gap between continents in the realm of medical innovation. Today, we're honored to host Marie-Pier St-Laurent from the University of British Columbia. As part of our exclusive Specialist Interview series, Marie-Pier will be sharing valuable insights from her recent abstract presented at ASCO GU. Stay tuned as we delve into groundbreaking research that's shaping the future of oncological care. Visit us at www.ioncol.com for more thought-provoking content
Dr. Niels Van de Donk: Navigating the Horizon of CAR-T Treatment for RRMM

Dr. Niels Van de Donk: Navigating the Horizon of CAR-T Treatment for RRMM

2024.01.26
Editor's Note: In this captivating interview, Dr. Niels Van de Donk offers an extensive exploration of the recent advancements and future prospects in Chimeric Antigen Receptor T-cell (CAR-T) therapy for relapsed/refractory multiple myeloma (RRMM). Dr. Donk's insights, ranging from the dynamic landscape of CAR-T targets to pivotal studies like MAJESTEC-1, provide a comprehensive overview of the current status, challenges, and promising directions in the ever-evolving field of RRMM treatment.01 Oncology Frontier: Unpacking the Current Progress in CAR-T Targets for RRMM